Repros Therapeutics (RPRX) 1.70 $RPRX Repros Provides

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 8:18 PM

Repros Therapeutics (RPRX) 1.70 $RPRX

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
GlobeNewswire - Wed Jun 01, 3:01PM CDT
-- EU submission on track with anticipated registration decision expected Fall 2017
RPRX: 1.70 (+0.07)

Repros Reports Positive Clinical Data for Oral Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Wed May 18, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004
RPRX: 1.70 (+0.07)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 13.07 (+0.29), RPRX: 1.70 (+0.07)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 38.87 (+0.49), ARQL: 1.92 (+0.03), APRI: 0.47 (-0.01), RPRX: 1.70 (+0.07)

Repros Therapeutics reports 1Q loss
Automated Insights - Tue May 10, 8:19AM CDT
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Tuesday reported a loss of $4.8 million in its first quarter.
RPRX: 1.70 (+0.07)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 39.63 (+0.89), BIIB: 238.62 (+4.02), CNAT: 2.13 (+0.09), AMGN: 152.27 (+2.46), RPRX: 1.70 (+0.07), JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92), GWPH: 89.14 (+0.57), GERN: 2.75 (+0.08), AVEO: 0.98 (-0.01), ICPT: 154.26 (+6.16), AGIO: 48.50 (+1.43), NVS: 80.67 (+0.96)

Will Repros Therapeutics (RPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:56AM CDT
As of late, it has definitely been a great time to be an investor in Repros Therapeutics Inc. (RPRX).
RPRX: 1.70 (+0.07)

Repros (RPRX) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue May 03, 8:25AM CDT
With no approved products in its portfolio, investors will be focused on Repros' progress with its pipeline candidates as well as its cost projections.
OVAS: 5.36 (+0.11), JAZZ: 145.00 (+2.06), RPRX: 1.70 (+0.07), CHMA: 2.74 (+0.19)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.15 (-0.01), SGYP: 3.80 (unch), HRTX: 18.14 (+0.25), RPRX: 1.70 (+0.07)

Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday
ACCESSWIRE - Mon Apr 18, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RPRX, COOL, CLMT, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
UNXL: 1.53 (-0.05), COOL: 0.80 (+0.01), RPRX: 1.70 (+0.07), CLMT: 4.98 (+0.06)

Trending Stocks: Thursday's Top Trading Stock Investors Have Followed
ACCESSWIRE - Thu Apr 14, 11:07AM CDT
MIAMI, FL / ACCESSWIRE / April 14, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, SUNE, RPRX, and EXXI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EXXI: 0.13 (-0.01), COOL: 0.80 (+0.01), SUNE: 0.34 (unch), RPRX: 1.70 (+0.07)

4 Small Cap Stocks That Have To Be On Your Watchlist Today
ACCESSWIRE - Thu Apr 14, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, CLDX and FNJN are on high volume alert. We have been following RPRX and FELP all week this week. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CLDX: 4.57 (+0.12), RPRX: 1.70 (+0.07), FNJN: 1.78 (-0.06), FELP: 1.67 (+0.02)

Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3
ACCESSWIRE - Wed Apr 13, 12:28PM CDT
THE WOODLANDS, TX / ACCESSWIRE / April 13, 2016 / Repros Therapeutics Inc.® (NASDAQ: RPRX) reported that vaginal administration of Proellex at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.
RPRX: 1.70 (+0.07)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 30.65 (-0.68), RPRX: 1.70 (+0.07), AMAG: 24.89 (+0.43), ANIK: 51.10 (+0.83)

These Small Cap Stocks Are Getting Big Time Attention Today
ACCESSWIRE - Wed Apr 13, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / April 13, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, EMKR and SUNE are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EMKR: 6.13 (+0.02), SUNE: 0.34 (unch), RPRX: 1.70 (+0.07), FELP: 1.67 (+0.02)

Repros Reports Positive Clinical Data for Vaginal Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Tue Apr 12, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011
RPRX: 1.70 (+0.07)

Apricus Hits 52-Week Low on Unfavorable Fispemifene Data
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:00PM CDT
Apricus' (APRI) shares hit a new 52-week low on disappointing top-line results from a phase IIb proof-of-concept study on fispemifene.
EBS: 30.65 (-0.68), APRI: 0.47 (-0.01), RPRX: 1.70 (+0.07), AMAG: 24.89 (+0.43)

Repros Gives EU Update on Secondary Hypogonadism Drug
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 4:05PM CDT
Repros Therapeutics (RPRX) announced that it has initiated the process for obtaining marketing authorization for enclomiphene by the European Medicines Agency.
AGN: 233.51 (+4.96), RPRX: 1.70 (+0.07), ABBV: 61.31 (+0.92)

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
GlobeNewswire - Tue Mar 15, 3:01PM CDT
Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization for enclomiphene in the treatment of secondary hypogonadism by the European Medicines Agency (EMA).
RPRX: 1.70 (+0.07)

Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 8:40AM CDT
Repros Therapeutics (RPRX) reported a narrower-than-expected fourth-quarter 2015 loss of 26 cents per share.
RPRX: 1.70 (+0.07), AMAG: 24.89 (+0.43), ANIK: 51.10 (+0.83)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Texas Instruments' $2B Notes Fuel Acquisition Ambitions

Pushing Forward with Big Dollars Texas Instruments is setting the stage with an ambitious move by pricing $2.0 billion in investment-grade notes, preparing to shake things up with an acquisition. It's not every day you see a player like TXN dipping into the bond market with such confidence, yet here we are. Four series of senior unsecured notes are slated for issuance on...

Honeywell Aerospace Faces Lawsuit After Stock Tumbles 23%

Honeywell's Bumpy Ride Rattles Investors Something's brewing over at Honeywell Aerospace, Inc. (NASDAQ:HONA) and it's not your regular cup of joe. Investors, brace yourselves, because a securities fraud class action lawsuit is stacking up against them. With shares plummeting 23.16% in a whirlwind of a market day, it's kind of hard not to get a little riled up, isn't it?...

Flagstar Faces Heat: 9.2% Stock Drop Spurs Probe

Flagstar's Descent: What Led to the Stock Tumble? And here we go again with a big name in finance taking a hit right between the eyes. Flagstar Bank, under ticker NYSE:FLG, saw its shares plummet by over 9.2% on October 23, 2026. This isn't just a blip—it's a spill. The backdrop here is an eye-watering $12.9 billion loan book tied to rent-regulated apartment buildings....

Costa Rican Firms Target Aerospace Supply Chain Gains

Today's spotlight swings on a gutsy move by 10 Costa Rican aerospace companies hustling for a foothold on the global stage. These folks aren't just sitting back; they're throwing their hats in the ring at the NBAA-BACE shindig down in the neon glare of Las Vegas, aiming to muscle into the aerospace supply chain — a cold, hard leap that's a mix of grit and ambition....

San Ysidro Urgent Care Addresses Care Desert in San Diego

A Long Overdue Remedy in San Diego Healthcare access shouldn't be a roll of the dice based on where you live, but for too many folks in Southeastern San Diego, that’s been the sad reality. Today, though, there's a new twist in the tale. Blue Shield of California Promise Health Plan just dropped a hefty $1 million into an urgent care facility that’s more than bricks...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Ouma Connect Streamlines Surrogacy Medical Clearance

A Game Changer for Surrogacy Agencies When we talk about innovation, we often focus on the flashiest tech in finance or the buzz of a scorching hot stock. But here's Ouma Health, shifting gears in a sector many traders don't blink at—surrogacy. They're unveiling Ouma Connect, a portal pulling back the curtain on medical clearances for gestational-carrier candidates....

Netcapital's 28.62% Plunge: A Fraudulent Drama Unfolds

Netcapital: The Plunge Heard 'Round the Market There it is, clear as day—Netcapital’s (NASDAQ: NCPL) stock plummeting 28.62% like a lead balloon. Shareholders had to watch in horror as pieces of their investments seemed to evaporate, all thanks to a swirl of alleged fraud. You can't just shrug off accusations that a company you've betted on has been cooking its books,...

WuXi AppTec Boosts Guidance Amid Strong CRDMO Growth

Unpacking WuXi AppTec's Latest Performance Boost WuXi AppTec, the pharmaceutical giant, isn't just coasting on its past successes. The way they're riding the contract research, development, and manufacturing (CRDMO) train straight through Q1 to Q3 of 2026 shows they're not just here for show. They've hiked up the stakes with strong metrics across the board, warranting a...